文献速递哮喘

哮喘患者口服与吸入糖皮质激素相关的骨质疏松和脆性骨折风险:两项基于人群的巢式病例对照研究

Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies.
PubMed 文献 · Thorax · 2020-10-21

该研究利用CPRD与HES链接数据开展两项巢式病例对照研究,在哮喘队列中分别识别骨质疏松或脆性骨折患者并按性别、年龄和诊所匹配对照,采用条件logistic回归分析糖皮质激素暴露与结局的关联。结果显示口服与吸入糖皮质激素累积剂量及既往一年处方数量均与骨质疏松和脆性骨折风险呈剂量反应关系,且接受双膦酸盐治疗的患者比例较低。

要点

  • 口服糖皮质激素处方≥9次较0次者骨质疏松风险OR为4.50(95%CI 3.21–6.11),脆性骨折风险OR为2.16(95%CI 1.56–3.32)。
  • 吸入糖皮质激素处方≥11次较0次者骨质疏松风险OR为1.60(95%CI 1.22–2.10),脆性骨折风险OR为1.31(95%CI 1.02–1.68)。
  • 在≥9次口服糖皮质激素处方的患者中,骨质疏松与脆性骨折者接受至少一种双膦酸盐处方的比例分别仅为50.6%和48.4%。

核心结论

  • 口服或吸入糖皮质激素暴露是哮喘患者骨健康的独立危险因素。
  • 建议以维持哮喘控制所需的最低水平给予糖皮质激素。

研究设计与样本

  • 两项巢式病例对照研究,使用临床实践研究数据链(CPRD)与医院统计(HES)数据库的链接数据。
  • 在哮喘队列中分别识别骨质疏松或脆性骨折患者,并按性别、年龄和诊所匹配对照。
  • 采用条件logistic回归分析吸入与口服糖皮质激素暴露与骨质疏松或脆性骨折风险的关联。

主要发现

  • 既往一年口服与吸入糖皮质激素的累积剂量和处方数量均与骨质疏松或脆性骨折风险呈剂量反应关系。
  • 调整混杂因素后,口服糖皮质激素处方≥9次较0次者骨质疏松风险OR为4.50(95%CI 3.21–6.11),脆性骨折风险OR为2.16(95%CI 1.56–3.32)。
  • 吸入糖皮质激素处方≥11次较0次者骨质疏松风险OR为1.60(95%CI 1.22–2.10),脆性骨折风险OR为1.31(95%CI 1.02–1.68)。
  • 累积剂量影响类似,口服或吸入糖皮质激素累积剂量更高者风险更大。
  • ≥9次口服糖皮质激素处方且至少一种双膦酸盐处方的患者比例在骨质疏松和脆性骨折中分别为50.6%和48.4%。

关键数值与推荐

  • 口服糖皮质激素处方≥9次 vs 0次:骨质疏松OR 4.50(95%CI 3.21–6.11),脆性骨折OR 2.16(95%CI 1.56–3.32)。
  • 吸入糖皮质激素处方≥11次 vs 0次:骨质疏松OR 1.60(95%CI 1.22–2.10),脆性骨折OR 1.31(95%CI 1.02–1.68)。
  • ≥9次口服糖皮质激素处方者中至少一种双膦酸盐处方比例:骨质疏松50.6%,脆性骨折48.4%。

临床怎么用

  • 对哮喘患者应评估糖皮质激素累积暴露及骨质疏松和脆性骨折风险。
  • 在维持哮喘控制的前提下,尽量使用最低水平的糖皮质激素。
  • 对高累积糖皮质激素暴露者,关注双膦酸盐等骨保护治疗的使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhaled (ICS) and oral (OCS) corticosteroids are used widely in asthma; however, the risk of osteoporosis and fragility fracture (FF) due to corticosteroids in asthma is not well-established. METHODS: We conducted two nested case-control studies using linked data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) databases. Using an asthma cohort, we separately identified patients with osteoporosis or FF and gender-, age- and practice-matched controls. Conditional logistic regression was used to determine the association between ICS and OCS exposure, and the risk of osteoporosis or FF. The prevalence of patients receiving at least one bisphosphonate was also calculated. RESULTS: There was a dose-response relationship between both cumulative dose and number of OCS/ICS prescriptions within the previous year, and risk of osteoporosis or FF. After adjusting for confounders, people receiving more OCS prescriptions (≥9 vs 0) had a 4.50 (95% CI 3.21 to 6.11) and 2.16 (95% CI 1.56 to 3.32) increased risk of osteoporosis and FF, respectively. For ICS (≥11 vs 0) the ORs were 1.60 (95% CI 1.22 to 2.10) and 1.31 (95% CI 1.02 to 1.68). The cumulative dose had a similar impact, with those receiving more OCS or ICS being at greater risk. The prevalence of patients taking ≥9 OCS and at least one bisphosphonate prescription was just 50.6% and 48.4% for osteoporosis and FF, respectively. CONCLUSIONS: The findings suggest that exposure to OCS or ICS is an independent risk factors for bone health in patients with asthma. Steroid administration at the lowest possible level to maintain asthma control is recommended.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Chalitsios CV, Shaw DE, McKeever TM, et al. Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies. Thorax. 2020. PMID: 33087546. doi:10.1136/thoraxjnl-2020-215664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。